The FDA's Drugs@FDA database records a supplement dated 9 October to an abbreviated new drug application (ANDA 210968) for generic olanzapine. A supplement to a generic application usually covers manufacturing, labelling alignment or packaging changes, and the record itself gives no detail of what changed.
It does not signal a new indication, a new safety finding or a change in how olanzapine should be prescribed. Its main relevance is supply: olanzapine is widely used and generic availability affects cost. In India, olanzapine is long established and widely available as a generic; this US record has no bearing on CDSCO's position.
- No change to olanzapine prescribing follows from this record.
- Continue metabolic monitoring — weight, glucose and lipids — for anyone starting olanzapine.
- Check the FDA label directly if a patient asks about a specific generic product.
Why it matters
It keeps the regulatory record complete without implying news for prescribers.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free